News
-
CLINICAL NEWS | Agios Meets Clinical Proof-of-Concept in Anaemia Treatment for Adults with Lower-Risk MDS
On Monday, the specialized disease company announced the successful achievement of “proof-of-concept” in a Phase 2a trial involving AG-946, a pyruvate kinase (PK) activator aimed at treating anemia in patients…
Read More » -
CASGEVY | 1st Gene-Editing Therapy for Thalassaemia and SCD Approved in UK
Casgevy is the first medicine to be licensed that uses the innovative gene-editing tool CRISPR, for which its inventors were awarded the Nobel Prize in 2020. The therapy, developed by…
Read More » -
-
BREAKING NEW GROUND | The First-Ever Guidelines for Managing α-Thalassaemia
The Thalassaemia International Federation (TIF) is proud to present the first international-level guidelines for the management of a-thalassaemia, a comprehensive and indispensable resource for health professionals, researchers and all those…
Read More » -
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | LDH Improvements Lead to Better Outcomes in Fatigue and QoL
PNH is a rare anaemia known for causing blood cell destruction, which can be shown by LDH levels. The study compared two drugs, eculizumab and ravulizumab, to see how they…
Read More » -
TIF’s NEW e-COURSE | Enhance Your Understanding of EU Health Policy
To address this need, the Thalassaemia International Federation (TIF) has launched an e-course titled ‘EU Health Policy Course’, which offers a comprehensive and up-to-the-minute overview of EU health-related policies. The…
Read More » -
TIF2023 | 16th International Conference on Thalassaemia & Haemoglobinopathies, November 3-5
The Conference, organized in collaboration with the Federation of Malaysia Thalassaemia Societies, the Malaysia Hematology Society and the Malaysian Association of Paediatric Haematology & Oncology, and with the support of…
Read More » -
CLINICAL NEWS | Promising Outcomes Found with Stem Cell Transplant for Fanconi Anemia-related Leukemia, MDS
Two-thirds of patients who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) to treat myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) resulting from Fanconi anemia (FA) were still alive at…
Read More » -
POSITION PAPER | Strengthening the Resilience of EU Health Systems
Thalassaemia is more than just a rare condition in Europe; it is a pressing issue that requires prompt action. With shifting migration patterns and escalating healthcare costs, EU health systems…
Read More » -
THAL PALS PODCAST | New Episode on TIF’s NTDT Guidelines Out Now
Dr. Κevin Kuo, MD, MSc, Clinician Investigator, and Μrs. Laurice Levine, Thalassaemia Patient Advocate, talk to TIF’s Executive Director, Dr Androulla Eleftheriou, and Dr. Khaled Musallam, Chief Research Officer, MD,…
Read More »